Olivier Briand

List of Publications by Year
in descending order

103 papers	17,327 citations	30070 54 h-index	33894 99 g-index
104 all docs	104 docs citations	104 times ranked	17403 citing authors

#	Article	IF	Citations
1	Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. Circulation, 1998, 98, 2088-2093.	1.6	1,540
2	Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation. Physiological Reviews, 2009, 89, 147-191.	28.8	1,309
3	Activation of human aortic smooth-muscle cells is inhibited by PPARÎ± but not by PPARÎ³ activators. Nature, 1998, 393, 790-793.	27.8	1,104
4	PPAR-Î± and PPAR-Î³ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine, 2001, 7, 53-58.	30.7	1,075
5	Peroxisome Proliferator-activated Receptor Î± Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-ÎºB and AP-1. Journal of Biological Chemistry, 1999, 274, 32048-32054.	3.4	982
6	Sorting out the roles of PPARÂ in energy metabolism and vascular homeostasis. Journal of Clinical Investigation, 2006, 116, 571-580.	8.2	779
7	Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology, 2017, 152, 1679-1694.e3.	1.3	630
8	PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nature Reviews Endocrinology, 2017, 13, 36-49.	9.6	509
9	Peroxisome Proliferator-Activated Receptor Activators Inhibit Thrombin-Induced Endothelin-1 Production in Human Vascular Endothelial Cells by Inhibiting the Activator Protein-1 Signaling Pathway. Circulation Research, 1999, 85, 394-402.	4.5	489
10	Peroxisome Proliferator-Activated Receptors and Atherogenesis. Circulation Research, 2004, 94, 1168-1178.	4.5	471
11	The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice. Journal of Biological Chemistry, 2006, 281, 11039-11049.	3.4	463
12	Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. Journal of Clinical Investigation, 2006, 116, 1052-1062.	8.2	447
13	Molecular Actions of PPARÎ± in Lipid Metabolism and Inflammation. Endocrine Reviews, 2018, 39, 760-802.	20.1	420
14	Statin-induced inhibition of the Rho-signaling pathway activates PPARÎ± and induces HDL apoA-I. Journal of Clinical Investigation, 2001, 107, 1423-1432.	8.2	381
15	Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology, 2013, 58, 1941-1952.	7.3	355
16	PPAR control of metabolism and cardiovascular functions. Nature Reviews Cardiology, 2021, 18, 809-823.	13.7	299
17	Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nature Communications, 2015, 6, 7629.	12.8	274
18	Distinct but complementary contributions of PPAR isotypes to energy homeostasis. Journal of Clinical Investigation, 2017, 127, 1202-1214.	8.2	270

#	Article	IF	Citations
19	Regulation of Macrophage Functions by PPAR-Î±, PPAR-Î³, and LXRs in Mice and Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1050-1059.	2.4	262
20	Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity. Diabetes, 2011, 60, 1861-1871.	0.6	261
21	Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. Journal of Lipid Research, 2012, 53, 1723-1737.	4.2	241
22	Glucose Regulates the Expression of the Farnesoid X Receptor in Liver. Diabetes, 2004, 53, 890-898.	0.6	226
23	Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. Journal of Hepatology, 2006, 44, 732-741.	3.7	213
24	Bile Acid Metabolism and the Pathogenesis of Type 2 Diabetes. Current Diabetes Reports, 2011, 11, 160-166.	4.2	201
25	The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition. Journal of Biological Chemistry, 2005, 280, 29971-29979.	3.4	186
26	Oxidized phospholipids activate PPARÎ± in a phospholipase A2-dependent manner. FEBS Letters, 2000, 471, 34-38.	2.8	179
27	Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferatorâ€“Activated Receptor-Î± via Inhibition of the Protein Kinase C Signaling Pathway. Circulation Research, 2006, 98, 361-369.	4.5	157
28	Niemannâ€“Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochemical and Biophysical Research Communications, 2006, 340, 1259-1263.	2.1	156
29	Effects of the New Dual PPARÎ±/Î´ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism. Diabetes Care, 2011, 34, 2008-2014.	8.6	155
30	Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. Gut, 2018, 67, 271-283.	12.1	150
31	Bile???Acid???Sequestrants???and???the???Treatment of Type??2??Diabetes??Mellitus. Drugs, 2007, 67, 1383-1392.	10.9	149
32	Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 513-519.	2.4	129
33	Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes, Obesity and Metabolism, 2010, 12, 384-392.	4.4	124
34	Farnesoid X Receptor Inhibits the Transcriptional Activity of Carbohydrate Response Element Binding Protein in Human Hepatocytes. Molecular and Cellular Biology, 2013, 33, 2202-2211.	2.3	110
35	The novel selective PPARÎ± modulator (SPPARMÎ±) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis, 2016, 249, 200-208.	0.8	107
36	Peroxisome Proliferator-Activated Receptor Â Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets. Diabetes, 2006, 55, 1605-1613.	0.6	100

#	Article	IF	Citations
37	The Protein Kinase C Signaling Pathway Regulates a Molecular Switch between Transactivation and Transrepression Activity of the Peroxisome Proliferator-Activated Receptor Î±. Molecular Endocrinology, 2004, 18, 1906-1918.	3.7	97
38	Nuclear bile acid signaling through the farnesoid X receptor. Cellular and Molecular Life Sciences, 2015, 72, 1631-1650.	5.4	92
39	Statin Induction of Liver Fatty Acid-Binding Protein (L-FABP) Gene Expression Is Peroxisome Proliferator-activated Receptor-Î±-dependent. Journal of Biological Chemistry, 2004, 279, 45512-45518.	3.4	84
40	The nuclear receptor FXR is expressed in pancreatic Î²â€cells and protects human islets from lipotoxicity. FEBS Letters, 2010, 584, 2845-2851.	2.8	80
41	The Farnesoid X Receptor Regulates Adipocyte Differentiation and Function by Promoting Peroxisome Proliferator-activated Receptor-Î³ and Interfering with the Wnt/Î²-Catenin Pathways. Journal of Biological Chemistry, 2010, 285, 36759-36767.	3.4	79
42	Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3783-3794.	3.6	78
43	Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice. Laboratory Investigation, 2010, 90, 1457-1467.	3.7	77
44	PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E1063-E1069.	3.5	76
45	Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Letters, 2005, 579, 4076-4080.	2.8	72
46	A dynamic CTCF chromatin binding landscape promotes DNA hydroxymethylation and transcriptional induction of adipocyte differentiation. Nucleic Acids Research, 2014, 42, 10943-10959.	14.5	71
47	PPARÎ±, but not PPARÎ³, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1897-1902.	2.4	70
48	Phosphorylation of Farnesoid X Receptor by Protein Kinase C Promotes Its Transcriptional Activity. Molecular Endocrinology, 2008, 22, 2433-2447.	3.7	66
49	Peroxisome Proliferatorâ€"Activated Receptor-Î± Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1573-1579.	2.4	66
50	Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes. Diabetes, 2018, 67, 1310-1321.	0.6	64
51	The PPARÎ±/p16 ^{INK4a} Pathway Inhibits Vascular Smooth Muscle Cell Proliferation by Repressing Cell Cycleâ€"Dependent Telomerase Activation. Circulation Research, 2008, 103, 1155-1163.	4.5	61
52	Comparison of expression and regulation of the high-density lipoprotein receptor SR-BI and the low-density lipoprotein receptor in human adrenocortical carcinoma NCI-H295 cells. FEBS Journal, 1999, 261, 481-491.	0.2	56
53	Proteasomal degradation of retinoid X receptor Î± reprograms transcriptional activity of PPARÎ³ in obese mice and humans. Journal of Clinical Investigation, 2010, 120, 1454-1468.	8.2	56
54	PPARÎ²/Î´ Activation Induces Enteroendocrine L Cell GLP-1 Production. Gastroenterology, 2011, 140, 1564-1574.	1.3	55

#	Article	IF	Citations
55	Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR). Hepatology, 2014, 59, 2022-2033.	7.3	55
56	Control of nuclear receptor activities in metabolism by postâ€translational modifications. FEBS Letters, 2011, 585, 1640-1650.	2.8	53
57	Cross-talk Between Statins and PPARÎ± in Cardiovascular Diseases: Clinical Evidence and Basic Mechanisms. Trends in Cardiovascular Medicine, 2008, 18, 73-78.	4.9	51
58	LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice. Journal of Clinical Investigation, 2009, 119, 3830-3838.	8.2	47
59	The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism. Archives of Physiology and Biochemistry, 2012, 118, 102-111.	2.1	46
60	The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids. Scientific Reports, 2020, 10, 174.	3.3	45
61	Apolipoprotein AII Enrichment of HDL Enhances Their Affinity for Class B Type I Scavenger Receptor but Inhibits Specific Cholesteryl Ester Uptake. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1074-1081.	2.4	44
62	Activation of intestinal peroxisome proliferator-activated receptor-Â increases high-density lipoprotein production. European Heart Journal, 2013, 34, 2566-2574.	2.2	44
63	Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization. Trends in Endocrinology and Metabolism, 2014, 25, 235-244.	7.1	43
64	Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1. Gastroenterology, 2016, 150, 650-658.	1.3	41
65	The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis. Journal of Hepatology, 2018, 69, 1099-1109.	3.7	40
66	The Nuclear Orphan Receptor Nur77 Is a Lipotoxicity Sensor Regulating Glucose-Induced Insulin Secretion in Pancreatic Î²-Cells. Molecular Endocrinology, 2012, 26, 399-413.	3.7	38
67	Peroxisome Proliferator-Activated Receptors Mediate Pleiotropic Actions of Statins. Circulation Research, 2007, 100, 1394-1395.	4.5	33
68	The RBM14/CoAA-interacting, long intergenic non-coding RNA Paral1 regulates adipogenesis and coactivates the nuclear receptor PPARÎ³. Scientific Reports, 2017, 7, 14087.	3.3	33
69	Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. Biochimie, 2005, 87, 93-98.	2.6	32
70	FXRâ€deficiency confers increased susceptibility to torpor. FEBS Letters, 2007, 581, 5191-5198.	2.8	30
71	Intestine-Specific Regulation of PPARÎ± Gene Transcription by Liver X Receptors. Endocrinology, 2008, 149, 5128-5135.	2.8	29
72	Postprandial Circulating miRNAs in Response to a Dietary Fat Challenge. Nutrients, 2019, 11, 1326.	4.1	29

#	Article	IF	Citations
73	O-GlcNAcylation Links ChREBP and FXR to Glucose-Sensing. Frontiers in Endocrinology, 2014, 5, 230.	3.5	28
74	Intestinal bile acid receptors are key regulators of glucose homeostasis. Proceedings of the Nutrition Society, 2017, 76, 192-202.	1.0	27
75	SR-BI does not require raft/caveola localisation for cholesteryl ester selective uptake in the human adrenal cell line NCI-H295R. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1631, 42-50.	2.4	25
76	The Hepatic Orosomucoid/Î±1-Acid Glycoprotein Gene Cluster Is Regulated by the Nuclear Bile Acid Receptor FXR. Endocrinology, 2013, 154, 3690-3701.	2.8	24
77	Bile Acid Sequestrants: Glucose-Lowering Mechanisms. Metabolic Syndrome and Related Disorders, 2010, 8, S-3-S-8.	1.3	23
78	Early-glycation of apolipoprotein E: effect on its binding to LDL receptor, scavenger receptor A and heparan sulfates. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2002, 1583, 99-107.	2.4	21
79	Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2021, 123, 154844.	3.4	20
80	High-density-lipoprotein subfraction 3 interaction with glycosylphosphatidylinositol-anchored proteins. Biochemical Journal, 1997, 328, 415-423.	3.7	19
81	FXR overexpression alters adipose tissue architecture in mice and limits its storage capacity leading to metabolic derangements. Journal of Lipid Research, 2019, 60, 1547-1561.	4.2	19
82	Defective VLDL metabolism and severe atherosclerosis in mice expressing human apolipoprotein E isoforms but lacking the LDL receptor. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2004, 1684, 8-17.	2.4	17
83	Failing FXR expression in the liver links aging to hepatic steatosis. Journal of Hepatology, 2014, 60, 689-690.	3.7	15
84	The Elongation Complex Components BRD4 and MLLT3/AF9 Are Transcriptional Coactivators of Nuclear Retinoid Receptors. PLoS ONE, 2013, 8, e64880.	2.5	14
85	Derivatives of Iressa, a Specific Epidermal Growth Factor Receptor Inhibitor, are Powerful Apoptosis Inducers in PC3 Prostatic Cancer Cells. ChemMedChem, 2007, 2, 318-332.	3.2	13
86	Palmitate increases <i>Nur77</i> expression by modulating ZBP89 and Sp1 binding to the <i>Nur77</i> proximal promoter in pancreatic Î²â€cells. FEBS Letters, 2013, 587, 3883-3890.	2.8	13
87	<scp>PPAR</scp>Î± is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke. Fundamental and Clinical Pharmacology, 2014, 28, 294-302.	1.9	12
88	Intestinal Lipid Metabolism Genes Regulated by miRNAs. Frontiers in Genetics, 2020, 11, 707.	2.3	12
89	Soaping Up Type 2 Diabetes With Bile Acids?. Diabetes, 2013, 62, 3987-3989.	0.6	11
90	Intestinal miRNAs regulated in response to dietary lipids. Scientific Reports, 2020, 10, 18921.	3.3	11

#	Article	IF	Citations
91	Retrograde cholesterol transport in the human Caco-2/TC7 cell line: a model to study trans-intestinal cholesterol excretion in atherogenic and diabetic dyslipidemia. Acta Diabetologica, 2017, 54, 191-199.	2.5	10
92	Metabolic effects of bile acid sequestration. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 138-144.	2.3	9
93	Farnesoid X Receptor Activation in Brain Alters Brown Adipose Tissue Function via the Sympathetic System. Frontiers in Molecular Neuroscience, 2021, 14, 808603.	2.9	9
94	Human free apolipoprotein A-I and artificial pre-beta-high-density lipoprotein inhibit eNOS activity and NO release. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2004, 1683, 69-77.	2.4	8
95	Characterization of one anastomosis gastric bypass and impact of biliary and common limbs on bile acid and postprandial glucose metabolism in a minipig model. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E772-E783.	3.5	8
96	Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism. Nutrients, 2022, 14, 2707.	4.1	8
97	Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption. , 2022, 1, 299-312.		5
98	Measuring biomarkers to assess the therapeutic effects of PPAR agonists?. Pharmacogenomics, 2007, 8, 1567-1580.	1.3	4
99	Endospanin-2 enhances skeletal muscle energy metabolism and running endurance capacity. JCI Insight, 2018, 3, .	5.0	4
100	4.P.348 Caveolae and glycosyl phosphatidylinositol-anchored proteins: A specific binding membrane domain for high density lipoproteins. Atherosclerosis, 1997, 134, 369.	0.8	1
101	Th-W60:3 Acute anti-inflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the PKC signalling pathway. Atherosclerosis Supplements, 2006, 7, 487.	1.2	1
102	Apolipoprotein AII is a better ligand than apolipoprotein AI for the human HDL receptor SR-BI but alters specific cholesteryl ester uptake in human adrenal cell line. Atherosclerosis, 1999, 144, 81.	0.8	0
103	Localisation of SR-BI in caveolae is not required for cholesteryl esters selective uptake in NCI H295R adrenal cell line. Atherosclerosis, 1999, 144, 110-111.	0.8	0